GlassScriptPhysician profile
James V Han
NPI 1144675414
$47,135.18
in general payments reported to CMS, 2019-2025
36 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $856 · 2022: $888 · 2023: $2,429 · 2024: $5,899 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $8,522 · Travel and Lodging: $1,619 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,095.00 |
| Food and Beverage | $8,521.98 |
| Travel and Lodging | $1,619.21 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38,785.95 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $3,203.65 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $929.25 | 2021-2025 | Tremfya, Stelara, Simponi |
| Conmed Corporation | $536.52 | 2021-2025 | Conmed Biopsy, Conmed Eus |
| Genzyme Corporation | $533.43 | 2022-2025 | |
| Boston Scientific Corporation | $315.24 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $293.66 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.44 | 2021-2024 | Xifaxan, Relistor |
| Janssen Scientific Affairs, LLC | $256.32 | 2021-2022 | |
| Pfizer INC. | $241.30 | 2022-2025 | |
| Gilead Sciences, INC. | $191.13 | 2023-2025 | |
| Ardelyx, INC. | $148.57 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $146.55 | 2023 | |
| Medtronic, INC. | $129.55 | 2022 | |
| Lilly USA, LLC | $125.01 | 2025 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $120.08 | 2021 | |
| Ironwood Pharmaceuticals, INC | $108.07 | 2022-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $84.31 | 2023-2024 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $72.78 | 2022-2025 | Sutab, Suflave |
| Celltrion USA INC. | $72.00 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $71.31 | 2022-2025 | Ocaliva |
| Inspire Medical Systems, INC. | $69.58 | 2025 | Inspire |
| Intra-Sana Laboratories | $50.00 | 2023 | Reltone 400 Mg, Reltone 200 Mg |
| Novo Nordisk INC | $49.96 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $37.47 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $36.13 | 2024 | |
| Mallinckrodt Hospital Products INC. | $35.51 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $33.91 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Madrigal Pharmaceuticals | $31.21 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $30.60 | 2025 | The Cologuard Plus Collection Kit |
| Ipsen Biopharmaceuticals, INC | $25.03 | 2025 | Iqirvo |
| Orphalan INC | $23.55 | 2025 | Cuvrior |
| Echosens North America, INC. | $16.60 | 2025 | Fibroscan |
| Capsovision, INC. | $15.98 | 2024 | Capsocam Plus |
| Digestive Care, INC. | $15.67 | 2024 | Pertzye |
| Phadia US INC. | $13.86 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.